Startups Collaborate with Galaxy in New Effort to Increase Alzheimer’s Patient Participation in Research

Startups Collaborate with Galaxy in New Effort to Increase Alzheimer’s Patient Participation in Research
Roobirk and Antidote, two startup companies that work to empower people living with Alzheimer’s disease have entered a partnership with Galaxy, an online portal to initiatives that facilitate patient participation in Alzheimer’s research. More than 80% of clinical studies overall are delayed or closed because not enough patients meet enrollment requirements. The problem is particularly severe in Alzheimer’s research which

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. John Dauphinais says:

    Anavex Life Sciences (AVXL) is currently enrolling for a Phase 3 Trial related to an Alzheimer’s treatment that slows and possibly stops the progression of the disease at the root level. Please check them out as they are legitimate, and also working with the Michael J. Fox Foundation to further a cure for Parkinson’s. Both diseases are neurodegenerative in nature and Anavex’s drug platform for both diseases has a similar method of action or delivery via the Sigma one receptor. Thanks for the read.

Leave a Comment

Your email address will not be published. Required fields are marked *